top of page
Search

EMA Draft Guidance- How To Approach the Protection Clinical Trial Information System (CTIS)

Writer's picture: Sharan MuruganSharan Murugan
Apr 10, 20222 min read

On 7 April 2022, European Medicines Agency released a draft guidance document on how to approach the protection of personal data and commercially confidential information in documents uploaded and published in the Clinical Trial Information System.


The Regulation aims to foster innovation through simplification of the clinical trial application process and to increase transparency and availability of information on clinical trials and their results.

The agency, in collaboration with the Member States and the European Commission (EC), has the obligation to set up and maintain a EU Portal as a single entry point for the submission of data and documents relating to clinical trials and a EU Database containing the data and documents submitted via the EU Portal in accordance with the Regulation.


The EU Database should contain all relevant information as regards the clinical trials submitted through the EU Portal. To ensure transparency of clinical trials, the EU Database should be publicly accessible and data should be presented in an easily searchable format.


This guidance document focuses on the following areas:

  • Description of the CTIS structure and components including a description of the functionalities and publication rules for clinical trials information submitted to the CTIS (chapter 2)

  • The protection of personal data as part of the clinical trial information submitted to CTIS (chapter 3)

  • The protection of commercially confidential information (CCI) as part of the clinical trial information submitted to CTIS (chapter 4)

  • The protection of personal data and CCI in inspection reports (chapter 5)

The CTR sets out requirements for the protection of personal data, CCI and increased transparency of 1clinical trials in the EU. These requirements apply to information contained in the EU Database.


Click this LINK to know more detailed information on how to approach the protection of personal data and commercially confidential information in documents uploaded and published in the Clinical Trial Information System.

175 views0 comments

Comments

I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page